Artiva Biotherapeutics (ARTV) Retained Earnings (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Retained Earnings for 4 consecutive years, with -$354.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 32.62% year-over-year to -$354.1 million; the TTM figure through Mar 2026 stood at -$354.1 million (down 32.62% YoY), while the FY2025 annual figure was $103000.0, up 100.04% from the prior year.
• Retained Earnings eased to -$354.1 million in Q1 2026 per ARTV's latest filing, from $103000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $308000.0 in Q4 2023 and bottomed at -$354.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$154.0 million across 4 years, with a median of -$230.6 million in 2024.
• On a YoY basis, Retained Earnings climbed as much as 100.04% in 2025 and fell as far as 238281.82% in 2025.
• Artiva Biotherapeutics' Retained Earnings stood at $308000.0 in 2023, then sank by 80192.21% to -$246.7 million in 2024, then jumped by 100.04% to $103000.0 in 2025, then tumbled by 343886.41% to -$354.1 million in 2026.
• Business Quant data shows ARTV's Retained Earnings at -$354.1 million in Q1 2026, $103000.0 in Q4 2025, and $87000.0 in Q3 2025.